Vaxxas, Inc.
Industry
- Pharmaceuticals
- Drug Delivery
- Transdermal
- Vaccines
- Drug Delivery
- Medical Devices
- Biotechnology
- Nanotechnology, Chips, etc.
Other Names/Subsidiaries
- Vaxxas Pty Ltd
Latest on Vaxxas, Inc.
Venture capital funding for biopharmaceutical companies overall may be down in 2023, but that does not mean that investors have stopped placing big bets on the industry. Three companies announced rece
The University of Texas MD Anderson Cancer Center and US/UK biotech Replay announced on 14 February that they are launching a new company, Syena, to advance research conducted at the cancer center o
The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece
Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license